Outcome of tacrolimus treatment in steroid-refractory or -dependent ulcerative colitis - experience in 220 patients
KJ Schmidt(Universitäres Kinderwunschzentrum Lübeck), Jürgen Büning(University Hospital Schleswig-Holstein), Klaus Fellermann(Apple (Israel)), J Emmrich(University of Rostock), EF Stange(Robert Bosch Hospital), K Herrlinger(Robert Bosch Hospital), Nicole Müller(Universitäres Kinderwunschzentrum Lübeck), H. Lehnert(University Hospital Schleswig-Holstein), Axel Dignaß(Goethe University Frankfurt)
Cited by 0
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
|Journal of Crohn s and Colitis|2014|1.1k
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969
NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression
|Gut|2004|798
A Chromosome 8 Gene-Cluster Polymorphism with Low Human Beta-Defensin 2 Gene Copy Number Predisposes to Crohn Disease of the Colon
|The American Journal of Human Genetics|2006|566